Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Deisseroth and colleagues used a novel optogenetic system to pace the heart and determine whether an increase in heart rate can evoke anxiety-like behaviours.
Findings from the DREAM-HF trial, the largest clinical trial of cell therapy in heart failure with reduced ejection fraction (HFrEF) to date, suggest that cardiac therapy with mesenchymal precursor cells might benefit patients with HFrEF, particularly those with inflammation.
The non-nutritive sweetener erythritol, a widely used sugar substitute, is associated with an increased risk of cardiovascular disease, including myocardial infarction and stroke, according to a new study.
Adenine base editing can be used to correct a genetic variant in preclinical models of hypertrophic cardiomyopathy, and this approach could be applied to other monogenic cardiac diseases.
A legally mandated preparticipation screening programme for all young people in Italy engaging in competitive sports has resulted in a very low rate of sports-related cardiac arrest and sudden cardiac death.
Researchers have engineered a wearable device that adheres to the skin and uses ultrasound imaging and a deep learning model to produce a dynamic, real-time assessment of cardiac function.
A subpopulation of cardiac-resident macrophages protect the heart against sepsis-induced cardiomyopathy by scavenging dysfunctional mitochondria ejected from cardiomyocytes; modulation or administration of these macrophages might be a potential therapeutic strategy.
In treatment-naive patients with essential hypertension, supplementation with prebiotic acetylated and butyrylated high amylose maize starch significantly reduces systolic blood pressure levels compared with placebo.
A new study shows that age-dependent nuclear remodelling in cardiomyocytes (via age-related loss of nuclear lamins) contributes to cardiac dysfunction through a process that is conserved in flies, mice and nonhuman primates.
A machine learning model trained using clinical data from electronic health records generated a novel in silico quantitative score for coronary artery disease
An intravascularly infused extracellular matrix preparation binds to leaky microvasculature, thereby localizing to inflamed tissues and promoting repair and regeneration, and potentially healing damaged tissues ‘from the inside out’.
Cytotoxic CD8+ T cells specific for the cardiac protein α-myosin heavy chain have a key role in immune-checkpoint-inhibitor-associated myocarditis, according to a study published in Nature.
In patients with paroxysmal, untreated atrial fibrillation (AF), first-line cryoballoon ablation is associated with a lower incidence of persistent AF compared with antiarrhythmic drug therapy, according to the 3-year follow-up data from the EARLY-AF trial.
In patients with chronic limb-threatening ischaemia who had an adequate conduit for vein bypass, bypass surgery is associated with fewer adverse events or deaths than an endovascular procedure, according to findings from the BEST-CLI trial.
The IRONMAN trial adds further support to the known benefits of intravenous iron therapy in patients with heart failure (HF) with reduced ejection fraction and iron deficiency, but narrowly misses the primary end point of hospitalization for HF and cardiovascular death.
Pemafibrate, a selective PPARα modulator, lowers plasma triglyceride levels but does not reduce the rate of major adverse cardiovascular events in patients already treated with optimal statin therapy, according to data from the PROMINENT trial.
Olpasiran, a small interfering RNA (siRNA) that reduces lipoprotein(a) (Lp(a)) production in the liver, administered every 12 weeks induces a pronounced and sustained decrease in the plasma levels of Lp(a) in patients with established atherosclerotic cardiovascular disease, according to findings from the OCEAN(a)-DOSE trial.
Some clinical observations suggest that female patients are more susceptible to myocarditis induced by immune-checkpoint-inhibitor therapies. A new study recapitulates this female predisposition in mice and provides mechanistic and biological plausibility, and suggests that hormone therapy could help to treat myocarditis by promoting the expression of MANF, a protein related to the unfolded protein response.
